Logo image of VX1.DE

VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis

FRA:VX1 - Deutsche Boerse Ag - US92532F1003 - Common Stock - Currency: EUR

342.75  +1.2 (+0.35%)

Fundamental Rating

7

Overall VX1 gets a fundamental rating of 7 out of 10. We evaluated VX1 against 69 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making VX1 a very profitable company, without any liquidiy or solvency issues. An interesting combination arises when we look at growth and value: VX1 is growing strongly while it also seems undervalued. These ratings could make VX1 a good candidate for value and growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

VX1 had positive earnings in the past year.
In the past year VX1 had a positive cash flow from operations.
Of the past 5 years VX1 4 years were profitable.
Of the past 5 years VX1 4 years had a positive operating cash flow.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

The Return On Assets of VX1 (15.13%) is better than 91.30% of its industry peers.
VX1's Return On Equity of 21.18% is amongst the best of the industry. VX1 outperforms 91.30% of its industry peers.
Looking at the Return On Invested Capital, with a value of 15.66%, VX1 belongs to the top of the industry, outperforming 92.75% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for VX1 is significantly above the industry average of 12.29%.
Industry RankSector Rank
ROA 15.13%
ROE 21.18%
ROIC 15.66%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

VX1 has a Profit Margin of 31.86%. This is amongst the best in the industry. VX1 outperforms 91.30% of its industry peers.
VX1's Operating Margin of 38.77% is amongst the best of the industry. VX1 outperforms 95.65% of its industry peers.
In the last couple of years the Operating Margin of VX1 has grown nicely.
VX1 has a Gross Margin of 86.11%. This is amongst the best in the industry. VX1 outperforms 81.16% of its industry peers.
In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
Industry RankSector Rank
OM 38.77%
PM (TTM) 31.86%
GM 86.11%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

7

2. Health

2.1 Basic Checks

VX1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for VX1 has been reduced compared to 1 year ago.
Compared to 5 years ago, VX1 has less shares outstanding
Compared to 1 year ago, VX1 has an improved debt to assets ratio.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

VX1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.6
WACC9.79%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

VX1 has a Current Ratio of 2.52. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
VX1 has a Current ratio (2.52) which is comparable to the rest of the industry.
A Quick Ratio of 2.16 indicates that VX1 has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.16, VX1 is in the better half of the industry, outperforming 63.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.52
Quick Ratio 2.16
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

8

3. Growth

3.1 Past

VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 7966.67%, which is quite impressive.
Measured over the past years, VX1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -44.14% on average per year.
The Revenue has grown by 10.46% in the past year. This is quite good.
The Revenue has been growing by 21.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%

3.2 Future

VX1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 151.19% yearly.
Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 10.04% on average per year.
EPS Next Y6211.74%
EPS Next 2Y753.07%
EPS Next 3Y332.19%
EPS Next 5Y151.19%
Revenue Next Year9.53%
Revenue Next 2Y10.08%
Revenue Next 3Y9.84%
Revenue Next 5Y10.04%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20 30

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 23.57 indicates a rather expensive valuation of VX1.
VX1's Price/Earnings ratio is rather cheap when compared to the industry. VX1 is cheaper than 84.06% of the companies in the same industry.
When comparing the Price/Earnings ratio of VX1 to the average of the S&P500 Index (26.76), we can say VX1 is valued inline with the index average.
A Price/Forward Earnings ratio of 18.92 indicates a rather expensive valuation of VX1.
Compared to the rest of the industry, the Price/Forward Earnings ratio of VX1 indicates a rather cheap valuation: VX1 is cheaper than 89.86% of the companies listed in the same industry.
VX1's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 34.91.
Industry RankSector Rank
PE 23.57
Fwd PE 18.92
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, VX1 is valued a bit cheaper than the industry average as 79.71% of the companies are valued more expensively.
VX1's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VX1 is cheaper than 82.61% of the companies in the same industry.
Industry RankSector Rank
P/FCF 29.3
EV/EBITDA 20.71
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

VX1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VX1 has an outstanding profitability rating, which may justify a higher PE ratio.
VX1's earnings are expected to grow with 332.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y753.07%
EPS Next 3Y332.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VX1!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERTEX PHARMACEUTICALS INC

FRA:VX1 (8/21/2025, 7:00:00 PM)

342.75

+1.2 (+0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners97.63%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap88.02B
Analysts75
Price Target435.14 (26.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.77%
Min EPS beat(2)-7.2%
Max EPS beat(2)3.67%
EPS beat(4)2
Avg EPS beat(4)-0.73%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.69%
EPS beat(8)5
Avg EPS beat(8)-64.33%
EPS beat(12)7
Avg EPS beat(12)-41.98%
EPS beat(16)10
Avg EPS beat(16)-30.63%
Revenue beat(2)1
Avg Revenue beat(2)-2.37%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.87%
Revenue beat(12)5
Avg Revenue beat(12)-0.45%
Revenue beat(16)8
Avg Revenue beat(16)0.05%
PT rev (1m)-2.66%
PT rev (3m)-5.15%
EPS NQ rev (1m)-0.11%
EPS NQ rev (3m)1.67%
EPS NY rev (1m)0%
EPS NY rev (3m)0.21%
Revenue NQ rev (1m)0.23%
Revenue NQ rev (3m)1.27%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.03%
Valuation
Industry RankSector Rank
PE 23.57
Fwd PE 18.92
P/S 8.98
P/FCF 29.3
P/OCF 26.66
P/B 5.97
P/tB 6.55
EV/EBITDA 20.71
EPS(TTM)14.54
EY4.24%
EPS(NY)18.11
Fwd EY5.28%
FCF(TTM)11.7
FCFY3.41%
OCF(TTM)12.86
OCFY3.75%
SpS38.16
BVpS57.4
TBVpS52.31
PEG (NY)0
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 15.13%
ROE 21.18%
ROCE 22.25%
ROIC 15.66%
ROICexc 23.06%
ROICexgc 25.99%
OM 38.77%
PM (TTM) 31.86%
GM 86.11%
FCFM 30.65%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexcg growth 3Y-29.98%
ROICexcg growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 173.52%
Cap/Sales 3.04%
Interest Coverage 260.41
Cash Conversion 83.13%
Profit Quality 96.21%
Current Ratio 2.52
Quick Ratio 2.16
Altman-Z N/A
F-Score6
WACC9.79%
ROIC/WACC1.6
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
EPS Next Y6211.74%
EPS Next 2Y753.07%
EPS Next 3Y332.19%
EPS Next 5Y151.19%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%
Revenue Next Year9.53%
Revenue Next 2Y10.08%
Revenue Next 3Y9.84%
Revenue Next 5Y10.04%
EBIT growth 1Y4.24%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year816.11%
EBIT Next 3Y130.8%
EBIT Next 5Y68.38%
FCF growth 1Y-9.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.45%
OCF growth 3YN/A
OCF growth 5YN/A